DERMATOLOGICALS IN THE

PHILIPPINES
Euromonitor International
May 2014

DERMATOLOGICALS IN THE PHILIPPINES

LIST OF CONTENTS AND TABLES

Headlines ..................................................................................................................................... 1
Trends .......................................................................................................................................... 1
Competitive Landscape ................................................................................................................ 2
Prospects ..................................................................................................................................... 2
Category Data .............................................................................................................................. 3
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6
Table 7

Sales of Dermatologicals by Category: Value 2008-2013 ............................ 3

Sales of Dermatologicals by Category: % Value Growth 2008-2013 ........... 3
NBO Company Shares of Dermatologicals: % Value 2009-2013 ................. 4
LBN Brand Shares of Dermatologicals: % Value 2010-2013 ....................... 4
LBN Brand Shares of Hair Loss Treatments: % Value 2010-2013 ............... 5
Forecast Sales of Dermatologicals by Category: Value 2013-2018 ............. 6
Forecast Sales of Dermatologicals by Category: % Value Growth
2013-2018 .................................................................................................... 6

Euromonitor International

Passport

DERMATOLOGICALS IN THE PHILIPPINES

DERMATOLOGICALS IN THE
PHILIPPINES
HEADLINES
Dermatologicals registers a 1% growth to reach Ps3 billion in 2013
Floods due to typhoons increase the risk of skin disease
Topical antifungals earns the highest value growth in 2013 at 5%
Johnson & Johnsons (Philippines) Inc leads dermatologicals with a 40% value share in 2013
Dermatologicals is predicted to post a constant value growth of below 1% over the forecast
period

TRENDS
The country is regularly hit by several storms that number as many as 20 per year. A heavy
downpour of rain accompanying typhoons usually results in flooded streets. This results in
damages not only to property but also to the state of health of individuals who come in contact
with floodwater as they are prone to suffer various skin diseases or infections.
Dermatologicals grew by 1% in value in 2013, marginally slowing down compared to 2012.
This is due to the availability of beauty and personal care products which are perceived as
suitable alternatives in treating mild cases. Antidandruff shampoos, for instance, can be used
to replace medicated shampoos, feminine wash for vaginal antifungals and antibacterial soap
for topical germicidals/antiseptics.
Topical antifungals registered the fastest value growth in 2013 at 5%. This is due to the
tropical climate in the country which makes ones skin susceptible to suffer fungal infection.
This is, especially true during the hot summer months as one easily perspires, making the
skin conducive to fungal growth since fungi thrive in moist areas. Also contributing to the
categorys growth is the frequent inclusion of topical antifungals amongst the healthcare
products provided for typhoon-stricken areas in anticipation of skin diseases that will be
sustained by individuals who were submerged in floods.
Though some new products entered the market, there were no significant innovations in
formulation, delivery mechanism or packaging. The majority are in the cream or ointment
format packaged in squeezable tubes with some using rigid plastic containers. Those in liquid
format, meanwhile, are packaged either in rigid plastic containers or glass bottles with some
using flexible packaging.
Nappy (diaper) rash treatments continued to be the only paediatric product with significant
value sales in 2013. Parents of infants are more likely to consult their physician for a more
accurate treatment of skin problems of their children. Popular brands for adults, meanwhile,
are deemed safe for use on school-aged children.
Amongst the dermatological products available in the market, vaginal antifungals hold the
potential to cause the greatest stigma amongst consumers, given the predominantly Catholic
population in the country. This is because the need for these products is somehow associated
with sexual promiscuity. Although popular feminine wash brands educate consumers that
infection can be caused by the monthly menstrual period, no visible efforts from companies of
major vaginal antifungal brands were seen to promote their products or inform consumers on
various causes of vaginal infection.

Euromonitor International

Passport

DERMATOLOGICALS IN THE PHILIPPINES

In 2012, it was estimated that 10% of the adult population was diabetic with 13% at risk of
developing the disease. Despite the high prevalence of diabetes, there were no prominent
dermatological brands positioned specifically for the treatment of diabetes-related skin
problems.
There were no switches for dermatologicals in 2013.

COMPETITIVE LANDSCAPE
Johnsons & Johnsons (Philippines) Inc continued to lead dermatologicals with a 40% value
share in 2013. This was due to the strong performance of its Nizoral brand. The dominance of
this brand is due to their high brand equity and adequate advertisements that sustain recall
amongst consumers.
International brands maintained their dominance in dermatologicals with local companies
accounting only for close to 15% of total value sales in 2013. The established product
development capability of multinational companies is an important advantage since it allows
them to introduce innovative products. Local companies, such as United Laboratories Inc,
meanwhile, compete through their generic brands which are competitively priced.
French brand Mustela, manufactured by Laboratoires Expanscience, was a recent market
entrant. It launched its Stelatopia line of products for babies whose skin is prone to eczema.
The brand is positioned towards high-end consumers with its distribution limited mainly to
upscale department stores. As such, it is not expected to significantly affect the market
performance of leading brands in dermatologicals.
A new option is available for those with haemorrhoid problems with the introduction of
Rowatanal Cream, being promoted locally by New Marketlink Pharmaceutical Corp. The
product is packaged in a squeezable tube that comes with a cannula nozzle for those who
require internal application.
Despite the higher retail price of branded products, they enjoy greater preference due the
consumer confidence they established through time. Private label products, though cheaper in
cost, remain few in number and provide a limited product range. Generics, meanwhile, are
able to lead in specific categories not dominated by branded products such as in
antiparasitics/lice treatments.

PROSPECTS
Flooding due to heavy rains is predicted to be a recurrent problem in the country. Though
typhoons are not inevitable, individuals are predicted to build on their knowledge of preventive
measures against skin problems that floodwater may bring. Antibacterial soap is expected to
be most utilised as the first defence against various skin diseases. This proactive stance is
predicted to hamper growth of dermatologicals, which is expected to register a marginal
constant value CAGR of below 1% over the forecast period.
The forecast for dermatologicals in the 2014 edition is not significantly restated versus that of
2013. Though the forecast constant value CAGR is below 1%, this is an improvement
compared to the 3% decline in CAGR over the review period. Haemorrhoid treatments is the
main driver for this improvement, expected to register the fastest constant value CAGR of 4%
over the forecast period. Aside from haemorrhoid treatments being one of the smaller
categories which holds more room for growth, the increasingly sedentary lifestyle and
unbalanced diet of consumers are projected to result in a greater need for this product.

Euromonitor International

Passport

DERMATOLOGICALS IN THE PHILIPPINES

Passport

The increasing incorporation of health-related benefits of various beauty and personal care
products poses a threat to the achievement of optimum growth of dermatologicals. Aside from
being more affordable, they are likewise more heavily advertised, which could potentially
make them common first options of individuals in treating their various skin or hair conditions.
Product development is predicted to be directed towards the use of more natural or traditional
ingredients. Dermatologicals positioned for infants and children are predicted to benefit most
in taking this direction, given that most parents prefer formulations which use fewer chemicals
for their childrens delicate skin. Dermatologicals specific for the needs of diabetics is likewise
predicted to be explored by companies, given the lack of products that are positioned to
address the unique skin concerns of those suffering from the disease.

CATEGORY DATA
Table 1

Sales of Dermatologicals by Category: Value 2008-2013

Ps million

Medicated Shampoos
Topical Antifungals
Vaginal Antifungals
Hair Loss Treatments
Nappy (Diaper) Rash
Treatments
Antiparasitics/Lice
(Head and Body)
Treatments
Antipruritics
Paediatric
Dermatologicals
Cold Sore Treatments
Haemorrhoid Treatments
Topical Allergy
Remedies/Antihistamines
Topical Germicidals/
Antiseptics
Dermatologicals
Source:

Table 2

2008

2009

2010

2011

2012

2013

862.5
564.2
94.3
321.1
115.1

845.3
586.7
96.1
330.8
119.7

819.9
619.0
97.6
339.0
125.1

787.1
646.9
98.6
345.8
131.1

779.2
679.2
99.1
349.3
137.0

769.1
709.8
99.4
354.5
142.9

40.8

41.3

41.8

42.1

42.3

42.4

85.9
-

86.4
-

86.8
-

87.2
-

87.4
-

87.6
-

48.1
-

50.5
-

52.7
-

55.0
-

57.2
-

59.3
-

563.1

564.8

565.9

566.5

568.2

571.0

2,695.0

2,721.5

2,747.9

2,760.1

2,798.8

2,836.0

Euromonitor International from official statistics, trade associations, trade press, company research,
store checks, trade interviews, trade sources

Sales of Dermatologicals by Category: % Value Growth 2008-2013

% current value growth

Medicated Shampoos
Topical Antifungals
Vaginal Antifungals
Hair Loss Treatments
Nappy (Diaper) Rash Treatments
Antiparasitics/Lice (Head and Body)
Treatments
Antipruritics
Paediatric Dermatologicals

Euromonitor International

2012/13

2008-13 CAGR

2008/13 Total

-1.3
4.5
0.3
1.5
4.3
0.3

-2.3
4.7
1.1
2.0
4.4
0.8

-10.8
25.8
5.4
10.4
24.1
4.0

0.2
-

0.4
-

2.0
-

DERMATOLOGICALS IN THE PHILIPPINES

Passport

Cold Sore Treatments

Haemorrhoid Treatments
Topical Allergy Remedies/Antihistamines
Topical Germicidals/Antiseptics
Dermatologicals
Source:

4.3
0.3
1.0

23.4
1.4
5.2

Euromonitor International from official statistics, trade associations, trade press, company research,
store checks, trade interviews, trade sources

Table 3

NBO Company Shares of Dermatologicals: % Value 2009-2013

% retail value rsp

Company
Johnson & Johnson
(Philippines) Inc
Dermpharma Inc
Mundipharma
Distribution GmbH
Bayer Philippines Inc
Pfizer Philippines Inc
Novartis Healthcare
Philippines Inc
Merck Sharp & Dohme
Philippines Inc
GlaxoSmithKline
Philippines Inc
United Laboratories Inc
Valeant Pharmaceuticals
(Phils) Inc
Lorenzo C Reyes
Laboratories Inc
Glenmark Philippines Inc
Pascual Laboratories Inc
Schering-Plough Corp
Chattem Inc
Sanofi-Synthlabo
Philippines Inc
Sanofi-Aventis
Philippines Inc
Others
Total
Source:

3.7
0.5
1.3

2009

2010

2011

2012

2013

42.7

42.9

42.9

41.9

40.3

11.7
-

11.9
9.2

12.1
9.2

12.0
9.3

12.1
9.3

6.0
6.5
3.2

6.2
6.4
3.1

6.2
6.4
3.2

6.3
6.4
3.2

6.4
6.4
3.2

2.4

2.5

3.0

3.1

1.5

1.6

1.7

2.3

2.5

2.4
-

2.2
-

1.9
-

1.9
-

1.9
1.4

1.1

1.1

1.1

1.0

1.0

1.2
8.9
2.4
-

1.1
-

1.0
-

0.9
-

0.9
-

12.3
100.0

12.0
100.0

11.8
100.0

11.7
100.0

11.5
100.0

Euromonitor International from official statistics, trade associations, trade press, company research,
store checks, trade interviews, trade sources

Table 4

LBN Brand Shares of Dermatologicals: % Value 2010-2013

% retail value rsp

Brand
Nizoral
Regroe
Betadine
Trosyd
Canesten

Euromonitor International

Company

2010

2011

2012

2013

Johnson & Johnson

(Philippines) Inc
Dermpharma Inc
Mundipharma
Distribution GmbH
Johnson & Johnson
(Philippines) Inc
Bayer Philippines Inc

32.8

32.8

32.6

32.4

10.5
9.2

10.6
9.2

10.6
9.3

10.6
9.3

7.5

7.5

7.7

7.9

6.2

6.2

6.3

6.4

DERMATOLOGICALS IN THE PHILIPPINES

Terramycin
Drapolene
Vandol
Varemoid
Minoxidil ISAC
United Home Sulfur
Caladryl
Katialis
Tinactin
Scalpex
Lamisil
Eurax
United Home
Whitfield's Ointment
Procto-Glyvenol
Caladryl
Desitin
Dermalin
Selsun
Monistat
Betadine
Caladryl
Desitin
Phisohex
Phisohex
Tinactin
Others
Total

Passport

Pfizer Philippines Inc

GlaxoSmithKline
Philippines Inc
Merck Sharp & Dohme
Philippines Inc
Novartis Healthcare
Philippines Inc
Dermpharma Inc
United Laboratories Inc
Valeant Pharmaceuticals
(Phils) Inc
Lorenzo C Reyes
Laboratories Inc
Merck Sharp & Dohme
Philippines Inc
Glenmark Philippines Inc
Novartis Healthcare
Philippines Inc
Novartis Healthcare
Philippines Inc
United Laboratories Inc

6.4
1.6

6.4
1.7

6.4
2.3

6.4
2.5

1.4

1.5

2.0

2.2

1.5

1.6

1.6

1.7

1.5
1.4
-

1.5
1.5
-

1.5
1.4
-

1.4
1.4
1.4

1.1

1.1

1.0

1.0

1.0

1.0

1.0

1.0

1.1
0.7

1.0
0.7

0.9
0.7

0.9
0.7

0.6

0.6

0.6

0.6

0.5

0.5

0.5

0.5

Novartis Healthcare
Philippines Inc
Johnson & Johnson
(Philippines) Inc
Johnson & Johnson
(Philippines) Inc
United Laboratories Inc
Chattem Inc
Johnson & Johnson
(Philippines) Inc
Pascual Laboratories Inc
Pfizer Philippines Inc
Pfizer Philippines Inc
Sanofi-Aventis
Philippines Inc
Sanofi-Synthlabo
Philippines Inc
Schering-Plough Corp

0.3

0.3

0.3

0.3

1.4

1.4

1.4

1.3

1.3

0.3

0.2
-

12.0
100.0

11.8
100.0

11.7
100.0

11.5
100.0

Source:

Euromonitor International from official statistics, trade associations, trade press, company research,
store checks, trade interviews, trade sources

Table 5

LBN Brand Shares of Hair Loss Treatments: % Value 2010-2013

% retail value rsp

Brand
Regroe
Minoxidil ISAC
Others
Total
Source:

Company

2010

2011

2012

2013

Dermpharma Inc
Dermpharma Inc

84.7
11.9
3.4
100.0

84.8
11.8
3.4
100.0

84.8
11.7
3.5
100.0

85.0
11.5
3.5
100.0

Euromonitor International from official statistics, trade associations, trade press, company research,
store checks, trade interviews, trade sources

Euromonitor International

DERMATOLOGICALS IN THE PHILIPPINES

Table 6

Passport

Forecast Sales of Dermatologicals by Category: Value 2013-2018

Ps million

Medicated Shampoos
Topical Antifungals
Vaginal Antifungals
Hair Loss Treatments
Nappy (Diaper) Rash
Treatments
Antiparasitics/Lice
(Head and Body)
Treatments
Antipruritics
Paediatric
Dermatologicals
Cold Sore Treatments
Haemorrhoid Treatments
Topical Allergy
Remedies/Antihistamines
Topical Germicidals/
Antiseptics
Dermatologicals
Source:

Table 7

2013

2014

2015

2016

2017

2018

769.1
709.8
99.4
354.5
142.9

742.2
724.0
100.3
356.3
145.7

719.9
740.6
102.4
361.6
148.8

701.9
759.1
104.9
368.9
152.1

687.9
780.4
108.1
378.1
155.6

677.6
803.8
111.8
389.4
159.3

42.4

41.6

40.9

40.5

40.3

40.2

87.6
-

85.4
-

83.7
-

82.5
-

81.6
-

81.2
-

59.3
-

61.1
-

63.2
-

65.8
-

68.7
-

72.2
-

571.0

553.9

540.0

531.9

526.6

524.0

2,836.0

2,810.5

2,801.2

2,807.6

2,827.3

2,859.5

Euromonitor International from trade associations, trade press, company research, trade interviews,
trade sources

Forecast Sales of Dermatologicals by Category: % Value Growth 2013-2018

% constant value growth

Medicated Shampoos
Topical Antifungals
Vaginal Antifungals
Hair Loss Treatments
Nappy (Diaper) Rash Treatments
Antiparasitics/Lice (Head and Body) Treatments
Antipruritics
Paediatric Dermatologicals
Cold Sore Treatments
Haemorrhoid Treatments
Topical Allergy Remedies/Antihistamines
Topical Germicidals/Antiseptics
Dermatologicals
Source:

2013-18 CAGR

2013/18 TOTAL

-2.5
2.5
2.4
1.9
2.2
-1.1
-1.5
4.0
-1.7
0.2

-11.9
13.2
12.6
9.8
11.5
-5.2
-7.3
21.7
-8.2
0.8

Euromonitor International from trade associations, trade press, company research, trade interviews,
trade sources

Euromonitor International